In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

An update on peripartum cardiomyopathy

ESC Congress 2010

Pregnancy and Heart Disease


The present status of peripartum cardiomyopathy (PPCM) was reviewed by four world experts. The two most striking features were that a probable pathology call mechanism has begun to emerge in the form of cleavage of prolactin to produce a sub-fraction that appears to have many damaging properties as far as the heart is concerned and that this can be blocked in mice by bromocriptine. Preliminary studies in humans suggest that bromocriptine is a valuable therapeutic agent but more rigorous studies are needed before its place is established.

The second striking feature highlighted by the session was the lack of large carefully designed studies to determine the incidence and outcome and also the extent to which recovery of LV function occurs and the risk of recurrence and mortality in future pregnancies. The present consensus is that PPCM is more common in Afro-Caribbean patients with “hotspots” identified in Haiti and Nigeria. The relationship of PPCM to other forms of cardiomyopathy remains to be defined.

References


148

SessionTitle:

An update on peripartum cardiomyopathy

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.